Anker Lundemose

CEO

Mission Therapeutics

Dr Anker Lundemose is the Chief Executive Officer of Mission Therapeutics, a company focused on deubiquitylating enzyme drug discovery and development. He is a serial entrepreneur and founder of several successful biotech companies, and has a broad international pharma, biotech and investor network. He is currently on the board of Inthera Therapeutics and Antag Therapeutics. Prior to joining Mission Therapeutics, he was CEO of Bionor Pharma, and owner and Managing Partner of BioTesch Advice & Consultancy. Previously he was co-founder and CEO of Prosidion, the UK spin-out of OSI Pharmaceuticals’ diabetes and obesity assets, which was subsequently reversed into OSI Pharmaceuticals, Inc. At OSI Pharmaceuticals, he was Executive Vice President Corporate Development & Strategy Officer, OSI, New York. Notably he was responsible for the acquisition of the DP-IV patent estate from Probiodrug and involved in the sale of OSI Pharmaceuticals to Astellas Pharma. He is a qualified medical doctor and has a D.MSc and a PhD from the University of Aarhus, Denmark.